Chairman of the Executive Committee, CEO
Mr. JeanChristophe Tellier has served as Chairman of the Executive Committee, Chief Executive Officer, Executive Director of UCB S.A. since January 1, 2015. Before that, he was Member of the Executive Committee, Executive Vice President and President of European Operations of the Company from July 1, 2011. He joined the Company from Ipsen where he was President General Manager Ipsen US. His role at Ipsen was to strengthen Ipsen specialty care business in North America, in the areas of endocrinology and neurology. He joined Ipsen in May 2009. He started his career in 1988 in the marketing department of Synthelabo and joined Ciba France as Group Marketing Manager in 1990 and got various marketing sales position until leading the Marketing Sales department. In 1997, following the merger of Ciba and Sandoz to form Novartis, he was appointed Head of the Mass Market Business unit in France until the end of 1999 where he became Chief Operating Officer of Novartis France. From 2003 to mid2006, JC Tellier was Chief Executive Officer of Novartis Pharma Belgium and during his tenure was elected president of Pharma.be, the Pharma trade association. At the end of 2006, he was promoted to Head of the Global Arthritis, Bone and Muscle disease Business Franchise at Novartis Headquarters in Basel, Switzerland. In February 2007, he was appointed Chairman and CEO of Novartis Pharma France and Novartis Group France until mid 2008 when he decided to join MacroGenics Inc., a Marylandbased biotechnology company, as Executive Vice President and Chief Commercial Officer. He is physician specialized in rheumatology and followed diverse executive training both at INSEAD and Harvard.
Age: 58 Chairman Since 2015
Management EfficiencyThe company has return on total asset (ROA) of 6.67 % which means that it generated profit of $6.67 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 13.73 % meaning that it generated $13.73 on every $100 dollars invested by stockholders.
Entity SummaryUCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. UCB SA was founded in 1928 and is based in Brussels, Belgium. UCB SA operates under Biotechnology classification in USA and traded on OTC Market. It employs 7478 people.UCB SA (UCBJY) is traded on OTC Market in USA. It is located in All?e de la Recherche, 60 and employs 7,478 people.
UCB SA Leadership Team
Stock Performance Indicators
Also Currentnly Active
Purchased over 300 shares of
Purchased over 70 shares of